AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein-glutamine gamma-glutamyltransferase 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P49221

UPID:

TGM4_HUMAN

Alternative names:

Fibrinoligase; Prostate transglutaminase; Prostate-specific transglutaminase; Transglutaminase P; Transglutaminase-4

Alternative UPACC:

P49221; Q16707; Q96QN4

Background:

Protein-glutamine gamma-glutamyltransferase 4, known by alternative names such as Fibrinoligase, Prostate transglutaminase, and Transglutaminase-4, plays a pivotal role in the mammalian reproductive process. It is instrumental in catalyzing the cross-linking of proteins and the conjugation of polyamines to specific proteins in the seminal tract, highlighting its critical function in fertility and reproductive health.

Therapeutic significance:

Understanding the role of Protein-glutamine gamma-glutamyltransferase 4 could open doors to potential therapeutic strategies. Its involvement in the seminal tract's biochemical processes makes it a target of interest for addressing reproductive health issues and enhancing fertility treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.